254 related articles for article (PubMed ID: 24375389)
21. Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma.
Gao YJ; Xin Y; Zhang JJ; Zhou J
World J Gastroenterol; 2008 Aug; 14(32):5000-7. PubMed ID: 18763281
[TBL] [Abstract][Full Text] [Related]
22. CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype.
Brandes JC; van Engeland M; Wouters KA; Weijenberg MP; Herman JG
Carcinogenesis; 2005 Jun; 26(6):1152-6. PubMed ID: 15760919
[TBL] [Abstract][Full Text] [Related]
23. Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer.
Tokunaga E; Oki E; Nishida K; Koga T; Yoshida R; Ikeda K; Kojima A; Egashira A; Morita M; Kakeji Y; Maehara Y
Breast Cancer Res Treat; 2006 May; 97(2):199-203. PubMed ID: 16502017
[TBL] [Abstract][Full Text] [Related]
24. Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression.
Privette LM; González ME; Ding L; Kleer CG; Petty EM
Cancer Res; 2007 Jul; 67(13):6064-74. PubMed ID: 17596595
[TBL] [Abstract][Full Text] [Related]
25. Pathobiologic implications of methylation and expression status of Runx3 and CHFR genes in gastric cancer.
Hu SL; Huang DB; Sun YB; Wu L; Xu WP; Yin S; Chen J; Jiang XD; Shen G
Med Oncol; 2011 Jun; 28(2):447-54. PubMed ID: 20300977
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic and genetic silencing of CHFR in esophageal adenocarcinomas.
Soutto M; Peng D; Razvi M; Ruemmele P; Hartmann A; Roessner A; Schneider-Stock R; El-Rifai W
Cancer; 2010 Sep; 116(17):4033-42. PubMed ID: 20564104
[TBL] [Abstract][Full Text] [Related]
27. CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel.
Wang X; Yang Y; Xu C; Xiao L; Shen H; Zhang X; Li T; Li X
Int J Gynecol Cancer; 2011 Aug; 21(6):996-1003. PubMed ID: 21792009
[TBL] [Abstract][Full Text] [Related]
28. Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer.
Takeshita M; Koga T; Takayama K; Yano T; Maehara Y; Nakanishi Y; Sueishi K
Cancer Biol Ther; 2010 Nov; 10(9):933-41. PubMed ID: 20855974
[TBL] [Abstract][Full Text] [Related]
29. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
30. Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer.
Yanokura M; Banno K; Kawaguchi M; Hirao N; Hirasawa A; Susumu N; Tsukazaki K; Aoki D
Oncol Rep; 2007 Jan; 17(1):41-8. PubMed ID: 17143476
[TBL] [Abstract][Full Text] [Related]
31. The anti-proliferative effects of the CHFR depend on the forkhead associated domain, but not E3 ligase activity mediated by ring finger domain.
Fukuda T; Kondo Y; Nakagama H
PLoS One; 2008 Mar; 3(3):e1776. PubMed ID: 18335050
[TBL] [Abstract][Full Text] [Related]
32. CHFR-associated early G2/M checkpoint defects in breast cancer cells.
Erson AE; Petty EM
Mol Carcinog; 2004 Jan; 39(1):26-33. PubMed ID: 14694445
[TBL] [Abstract][Full Text] [Related]
33. CHFR‑mediated epithelial‑to‑mesenchymal transition promotes metastasis in human breast cancer cells.
Jiang G; Fang H; Shang X; Chen X; Cao F
Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33880594
[TBL] [Abstract][Full Text] [Related]
34. CHFR protein regulates mitotic checkpoint by targeting PARP-1 protein for ubiquitination and degradation.
Kashima L; Idogawa M; Mita H; Shitashige M; Yamada T; Ogi K; Suzuki H; Toyota M; Ariga H; Sasaki Y; Tokino T
J Biol Chem; 2012 Apr; 287(16):12975-84. PubMed ID: 22337872
[TBL] [Abstract][Full Text] [Related]
35. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
[TBL] [Abstract][Full Text] [Related]
36. Promoter hypermethylation and silencing of CHFR mitotic stress checkpoint gene in human gastric cancers.
Kang HC; Kim IJ; Park JH; Shin Y; Park HW; Ku JL; Yang HK; Lee KU; Choe KJ; Park JG
Oncol Rep; 2004 Jul; 12(1):129-33. PubMed ID: 15201973
[TBL] [Abstract][Full Text] [Related]
37. CHFR promotes metastasis of human gastric carcinoma by activating AKT and ERK via NRF2- ROS axis.
He F; Ye B; Wu X; Pan J; Wang J; Wang X
BMC Gastroenterol; 2023 Apr; 23(1):114. PubMed ID: 37024798
[TBL] [Abstract][Full Text] [Related]
38. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
[TBL] [Abstract][Full Text] [Related]
39. Functional interaction between Chfr and Kif22 controls genomic stability.
Maddika S; Sy SM; Chen J
J Biol Chem; 2009 May; 284(19):12998-3003. PubMed ID: 19321445
[TBL] [Abstract][Full Text] [Related]
40. [Aberrant promoter hypermethylation of CHFR in nasopharyngeal carcinoma].
Huang T; Du C; Yu N; Xiao X; Zhou X; Wang S; Huang G; Zhang Z
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Aug; 25(16):746-50. PubMed ID: 22070084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]